← Back to Search

Semaglutide D Dose 1 for Type 2 Diabetes

Phase 1
Waitlist Available
Research Sponsored by Novo Nordisk A/S
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.
Awards & highlights

Study Summary

This trial is investigating two different tablet versions of semaglutide to see which stays in the bloodstream longer. It will last around 29-31 weeks and will have three different groups receiving varying lengths of treatment.

Eligible Conditions
  • Type 2 Diabetes
  • Healthy Subjects

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154.
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 hours after the dosing of oral semaglutide on days 35/42/49, 70/77/84, 105/112/119 and 140/147/154. for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
AUC0-24h,semaglutide,SS Area under the semaglutide plasma concentration-time curve during a dosing interval at steady state (SS)
Cmax,0-24h.semaglutide,SS Maximum semaglutide plasma concentration at steady state
Secondary outcome measures
Ctau,24h,semaglutide,SS Semaglutide plasma concentration 24 hours after last dose at steady state
tmax,0-24h,semaglutide,SS Time to maximum semaglutide plasma contraction at steady state

Trial Design

6Treatment groups
Experimental Treatment
Group I: Group 3 Sequence 2Experimental Treatment2 Interventions
Crossover arm
Group II: Group 3 Sequence 1Experimental Treatment2 Interventions
Crossover arm
Group III: Group 2 Sequence 2Experimental Treatment4 Interventions
Crossover arm
Group IV: Group 2 Sequence 1Experimental Treatment4 Interventions
Crossover arm
Group V: Group 1 Sequence 2Experimental Treatment4 Interventions
Crossover arm
Group VI: Group 1 Sequence 1Experimental Treatment4 Interventions
Crossover arm
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Semaglutide
FDA approved
Semaglutide
FDA approved
Semaglutide
FDA approved
Semaglutide
FDA approved
Semaglutide
FDA approved
Semaglutide
FDA approved

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

Novo Nordisk A/SLead Sponsor
1,513 Previous Clinical Trials
2,414,483 Total Patients Enrolled
Clinical Transparency (Dept. 2834)Study DirectorNovo Nordisk A/S
3 Previous Clinical Trials
2,295 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

To what extent is Semaglutide D Dose 1 a safe option for treatment?

"Our team at Power judged Semaglutide D's safety to be a 1, given that this is only the first phase of trials and there has been limited data collected regarding its efficacy."

Answered by AI

Do I fulfill the prerequisites to join this medical experiment?

"This clinical trial is enrolling 404 individuals with type 2 diabetes mellitus aged 18-64. To qualify for the study, applicants must meet the following requirements: Male or female between 18 to 64 years old (both inclusive) at time of signing informed consent; BMI range from 21.0 - 32.0 kg/m^2 (inclusive); and considered generally healthy based on medical history, physical examination results and vital signs checks as judged by investigator."

Answered by AI

Are new participants being invited to join this clinical trial currently?

"According to information posted on clinicaltrials.gov, this study is no longer recruiting candidates. It was initially published on February 4th 2022 and the latest update occurred November 10th 2022. Despite not being able to join this trial anymore, there are still over 1200 other medical trials actively seeking participants at present."

Answered by AI

Are senior citizens able to engage in this clinical endeavor?

"The eligibility requirements for this clinical trial demand that the participant is between 18 and 64 years old."

Answered by AI

Who else is applying?

What state do they live in?
California
Kansas
How old are they?
18 - 65
What site did they apply to?
Novo Nordisk Investigational Site
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
0
Recent research and studies
clinicaltrials.govStudy
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People
2022. "A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05227196.
~172 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top